Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6531
    +0.0031 (+0.48%)
     

  • OIL

    82.99
    +0.18 (+0.22%)
     

  • GOLD

    2,340.80
    +2.40 (+0.10%)
     

  • Bitcoin AUD

    97,625.41
    -4,364.68 (-4.28%)
     

  • CMC Crypto 200

    1,358.35
    -24.23 (-1.75%)
     

  • AUD/EUR

    0.6091
    +0.0021 (+0.34%)
     

  • AUD/NZD

    1.0958
    +0.0016 (+0.15%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,096.45
    +56.07 (+0.70%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    17,983.63
    -105.07 (-0.58%)
     

  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

Midday movers: Abercrombie & Fitch, Petco Health, Palo Alto Networks and more

Investing.com
·1-min read

Investing.com -- Stocks are falling on Wednesday as negotiations on the debt ceiling dragged on with the deadline swiftly approaching. Here are the market movers for May 24.

Abercrombie&Fitch Company (NYSE:ANF) shares jumped 27% as the specialty retailer reported a surprise profit for the first quarter and a gain in net sales, led by its namesake brand amid a reinvention. Shares of fellow retailer Kohl’s Corp (NYSE:KSS), which operates department stores, also jumped 7.7% after a surprise profit. Petco Health and Wellness Company Inc (NASDAQ:WOOF) shares fell 15% after the pet supply retailer provided weak revenue guidance for the current quarter. It beat expectations for the first quarter. Palo Alto Networks Inc (NASDAQ:PANW) shares rose 7.4% after the cybersecurity firm raised its guidance for profit, sales and billings for the fiscal year. Its third-quarter adjusted profit beat expectations. Intuit Inc (NASDAQ:INTU) shares fell 6.9% after the maker of financial software such as TurboTax reported third-quarter revenue below forecasts. While it raised its outlook for the full fiscal year, it gave a fourth-quarter profit estimate that fell short of expectations.

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares slid 11% after the biotech said the Food and Drug Administration was pushing back a decision date on its muscular dystrophy gene therapy by about a month.

Related Articles

Biden administration urges Supreme Court not to hear Apple-Caltech patent case

JPMorgan can sue former executive Staley over Epstein ties -US judge